Related Experiment Video
Updated: May 9, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells
Xiaofeng Yu1, Yinghua Pan, Housheng Ma
1Department of Thoracic Surgery, Yuhuangding Hospital, Yantai, Shandong, China. Xiaofeng273@yahoo.com.cn
Abstract:
Lung cancer is the one of the most frequent causes of malignant tumors. In recent years, it has been documented that statins have anticancer and cancer chemopreventive properties. However, the mechanism of simvastatin on lung cancer is still unclear. In this study, the human lung cancer cell line A549 cells were incubated with simvastatin. Simvastatin inhibited the survival of A549 cells in a dose-dependent manner, decreased Bcl-2 protein expression, and increased Bax protein expression time and dose dependently. In addition, simvastatin blocked cells in the G1 phase of the cell cycle, downregulated cyclin D1 and CDKs protein expression, mediated the mitochondria-dependent caspase cascade by increasing caspase-3, -8, and -9 mRNA and protein expression, downregulated Xiap levels to induce cells apoptosis. Importantly, simvastatin suppressed decreased MMP-9 protein expression and suppressed NF-κB activation in A549 cells. Taken together, these results showed that the anticancer effect of simvastatin in lung cancer A549 cells via the inhibiting cell proliferation, influencing the cell cycle, downregulating cyclin D1 and CDKs expression, inducing apoptosis, and decreasing MMP-9 levels, possibly by inhibiting the activation of NF-κB. Statins contribute to lung cancer therapy and may be an ideal anticancer and cancer chemopreventive agent for lung cancer.
Insights
Simvastatin, a statin drug, inhibits lung cancer cell growth and survival by inducing apoptosis and cell cycle arrest. It also reduces matrix metalloproteinase-9 (MMP-9) levels, suggesting potential as a lung cancer therapeutic agent.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Lung cancer remains a leading cause of cancer mortality worldwide.
- Statins, known for cholesterol-lowering, exhibit potential anticancer properties.
- The precise mechanisms of simvastatin's action on lung cancer are not fully understood.
Purpose of the Study:
- To investigate the anticancer effects and underlying mechanisms of simvastatin on human lung cancer A549 cells.
- To elucidate how simvastatin influences cell survival, cell cycle progression, apoptosis, and invasion-related factors.
Main Methods:
- A549 human lung cancer cells were treated with varying concentrations of simvastatin.
- Cell viability, protein expression (Bcl-2, Bax, cyclin D1, CDKs, caspase-3, -8, -9, Xiap, MMP-9), cell cycle distribution, and NF-κB activation were analyzed.
Main Results:
- Simvastatin inhibited A549 cell survival and proliferation in a dose-dependent manner.
- It induced apoptosis by altering Bcl-2/Bax ratios, activating caspases, and downregulating Xiap.
- Simvastatin caused G1 cell cycle arrest, downregulated cyclin D1 and CDKs, suppressed MMP-9 expression, and inhibited NF-κB activation.
Conclusions:
- Simvastatin demonstrates significant anticancer effects against lung cancer cells by inhibiting proliferation, arresting the cell cycle, inducing apoptosis, and reducing MMP-9 levels.
- These effects are potentially mediated through the inhibition of NF-κB activation.
- Simvastatin shows promise as a therapeutic and chemopreventive agent for lung cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:31The Intrinsic Apoptotic Pathway